FiercePharmaOriginal article
{"a":[{"_":"Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims","$":{"href":"/pharma/sandoz-floats-nearly-500m-resolve-bulk-lingering-us-antitrust-claims","hreflang":"en"}}]}
RegulatoryNegative
AI Analysis
Summary
Sandoz is proposing nearly $500M to settle U.S. antitrust claims in a manner similar to Johnson & Johnson's recent settlement strategy. The settlement would resolve the bulk of lingering antitrust litigation against the generics and biosimilars company.
Outcome Details
Settlement discussions to resolve antitrust claims
Importance:6/10
Sentiment:
-0.30
antitrustlitigationsettlementgenericsbiosimilars
Read the original article
Published by FiercePharma on August 3, 2026 9:29 AM
